MAYLING BARRERA: Open Payments
NPI 1205392339 · LAKEWOOD, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$399 in 20 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $201 · 2025 $399
Food & beverage: $399
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $80 |
| Merck Sharp & Dohme LLC | 3 | $68 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
| Lilly USA, LLC | 2 | $43 |
| PFIZER INC. | 2 | $34 |
| Amgen Inc. | 2 | $31 |
| ABIOMED | 1 | $27 |
| Novo Nordisk Inc | 1 | $22 |
| SCPHARMACEUTICALS INC. | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
Products named: CAMZYOS, VERQUVO, LOKELMA, ELIQUIS, REPATHA, ZEPBOUND, Wegovy, FUROSCIX.
Industry payments across WA — which companies pay providers there.
